| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Extracellular matrix-binding proteins from staphylococcus aureus | US09200650 | 1998-11-25 | US06680195B1 | 2004-01-20 | Joseph M. Patti; Timothy J. Foster; Elisabet Josefsson; Deidre Ni Eidhin; Magnus A. O. Hook; Samuel E. Perkins |
| Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD (SEQ ID NO: 16). | ||||||
| 82 | Method and apparatus for selective biological material detection | US09550777 | 2000-04-17 | US06376204B1 | 2002-04-23 | William T. Bodenhamer |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 83 | Method and apparatus for detection of multiple biological materials with a heterogeneous antibody mixture | US09837639 | 2001-04-17 | US20020009811A1 | 2002-01-24 | William T. Bodenhamer; George Jackowski; Eric Davies; Mansel Griffiths |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 84 | Diagnosis and treatment of bacterial dysentery | US868929 | 1997-06-04 | US5955449A | 1999-09-21 | Glen D. Armstrong; Robert M. Ratcliffe |
| Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT). | ||||||
| 85 | Diagnosis and treatment of bacterial dystentery | US453775 | 1995-05-30 | US5679653A | 1997-10-21 | Glen D. Armstrong; Robert M. Ratcliffe |
| Diagnostic and therapeutic compositions which comprise the .alpha.Gal(1-4).beta.Gal subunit are described. These compositions permit the rapid diagnosis and treatment of enteric infections caused by E. coli that produce shiga-like toxins (SLT). | ||||||
| 86 | 마이코플라즈마 뉴모니아의 면역학적 검출법 및 키트 | KR1020177022222 | 2016-01-27 | KR1020170106371A | 2017-09-20 | 사이토켄지 |
| (과제) 본발명은마이코플라즈마폐렴의원인균인마이코플라즈마뉴모니아를간편또한신속하게고감도검출을가능하게하는특이적항체, 또한상기항체를포함하는면역학적검출법및 키트를제공하는것을목적으로한다. (해결수단) 마이코플라즈마뉴모니아의 P30 단백질의특정에피토프를인식하는항체를제작하고상기항체를이용하여면역학적검출함으로써, 마이코플라즈마뉴모니아의감염을종래법보다신속또한특이적으로진단할수 있다. 본발명에의하면특수한기기및 숙련한기술을필요로하지않아, 병원등에있어서간편또한신속하게마이코플라즈마뉴모니아의검출및 감염을진단하는것이가능하게된다. | ||||||
| 87 | 미생물의 직물에의 부착을 감소시키는 방법 | KR1020167019831 | 2014-12-18 | KR1020160123290A | 2016-10-25 | 카첸마이어,하인츠; 스투테,페터; 슈미트-엠리히,사브리나; 퇴니-마이어,린다; 출리안,쿤렌 |
| 본발명은미생물, 특히박테리아및/또는효모의섬유및/또는직물에의부착을감소시키는것을목표로하는섬유및/또는직물을마감하는방법에관한것이다. 기술된방법은선택된친수성실란유도체를포함하는조성물 ZS를섬유및/또는직물에적용시키는것을포함한다. 본발명은더욱이미생물의섬유및/또는직물에의부착을정량하는방법에관한것이다. | ||||||
| 88 | 조류 레오바이러스 백신 | KR1020167020781 | 2015-01-29 | KR1020160113137A | 2016-09-28 | 셀러스,홀리,에스. |
| 본발명은미국동남부지역닭들의바이러스성관절염/건막염의임상사례로부터분리된조류레오바이러스의신규균주들에관한것이다. 본발명은이러한신규의제1군및 제2군조류레오바이러스, 이와같은바이러스들의뉴클레오티드- 또는아미노산-특이적성분들, 예를들어시그마 C 단백질을암호화하는 S1 유전자를사용하는진단분석법, 그리고이와같은바이러스들에의해유발된질병으로부터닭들을방어하는백신에관한것이다. | ||||||
| 89 | 암 치료용 예측 바이오마커 | KR1020157029934 | 2014-05-15 | KR1020150129860A | 2015-11-20 | 슈로프,마티아스; 슈미트,마누엘; 카프,커스틴; 비티히,버가트 |
| 본발명은일반적으로암에걸린환자가특정치료에반응할지여부를식별하는것에관한것이다. 보다상세하게, 본발명은치료제 TLR-9 아고니스트에대한반응자를식별하는방법및 수단에관한것이다. | ||||||
| 90 | Method for reducing adhesion of microorganisms to fabrics | US15104710 | 2014-12-18 | US10132029B2 | 2018-11-20 | Heinz Katzenmeier; Peter Stutte; Sabrina Schmidt-Emrich; Linda Thoeny-Meyer; Qun Ren Zulian |
| The present invention relates to a method for finishing fibers and/or fabrics, the intention being to reduce the adhesion of microorganisms, especially of bacteria and/or yeasts, to the fibers and/or fabrics. The method involves applying a composition ZS comprising selected hydrophilic silane derivatives to the fibers and/or fabrics. The invention further relates to a method for the quantitative determination of the adhesion of microorganisms to fibers and/or fabrics. | ||||||
| 91 | RISK STRATIFICATION IN INFLUENZA | US16017197 | 2018-06-25 | US20180298455A1 | 2018-10-18 | Anthony McLean; Benjamin Tang; Grant Peter Parnell; Maryam Shojaei |
| The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IFI27) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | ||||||
| 92 | Detection assays and methods | US15055217 | 2016-02-26 | US10006906B2 | 2018-06-26 | Abdennour Abbas |
| This disclosure describes assay methods and kits for detecting a target. The methods and kits can be used to detect a target that is present in a sample at low concentration because the methods and kits amplify the signal indicating the presence of target in the sample. Generally, the methods and kits involve nanoparticle aggregation as a detectable signal that is enhanced by a trigger released from a vesicular compartment when the target is bound to a capture agent. | ||||||
| 93 | Predictive biomarker for cancer therapy | US14891869 | 2014-05-15 | US10006032B2 | 2018-06-26 | Matthias Schroff; Manuel Schmidt; Kerstin Kapp; Burghardt Wittig |
| The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists. | ||||||
| 94 | Eukaryotic cells with artificial endosymbionts for multimodal detection | US15594594 | 2017-05-13 | US09814790B2 | 2017-11-14 | Caleb B. Bell, III; Alexey Bazarov |
| The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged. | ||||||
| 95 | Metal-Antibody Tagging and Plasma-based Detection | US15510319 | 2015-09-14 | US20170307533A1 | 2017-10-26 | Joseph Paul Robinson; Bartlomiej P. Rajwa; Valery P. Patsekin; Euiwon Bae |
| An apparatus and method for characterizing a target, e.g., microbial samples or biological toxins, includes labeling the target with a biomolecular recognition construct and measuring an atomic-spectra signal of the biomolecular recognition construct. The method can include heating the labeled target before measuring the atomic-spectra signal. The atomic-spectra signal can be measured by performing laser-induced breakdown spectroscopy. The atomic-spectra signal can be measured by performing spark induced breakdown spectroscopy. The biomolecular recognition construct can be prepared by tagging a biological scaffolding with a metal atom or ion. In an aspect in which the target includes a microbial sample, the biological scaffolding can include an antibody against epitopes present on bacterial surface, the antibody linked to a heavy metal. In an aspect in which the target includes a biological toxin, the biological scaffolding can include an antibody against the biological toxin linked to heavy metals. | ||||||
| 96 | Microstructured chip for surface plasmon resonance analysis, analysis device containing said microstructured chip and use of said device | US14354253 | 2012-10-25 | US09746467B2 | 2017-08-29 | Thibaut Mercey |
| A microstructured chip (3; 33; 43; 53; 63) for surface plasmon resonance (SPR) analysis, taking the form of a solid formed by: a base (5; 77); an upper surface (4; 44), at least part of which is covered with a metal layer (2; 22; 42; 52; 62); and at least one side surface (55; 66). The chip is characterized in that the aforementioned upper surface is provided with micrometric zones intended to receive species to be analyzed and selected from among n protrusions and m cavities, and in that when n+m≧2 the zones are separated from one another by planar surfaces, with n varying between 1 and j, m varying between 0 and i, and j and i being integers. | ||||||
| 97 | Target capture system | US14107315 | 2013-12-16 | US09599610B2 | 2017-03-21 | Ravil A. Sitdikov; Eddie W. Adams; Magdalena A. Torrance; David K. Aley; Erik J. Smith; Victor C. Esch |
| The invention generally relates to a system for isolating or separating a target from a sample. In certain aspects, processes performed by the target capture system include introducing a plurality of magnetic particles, in which a plurality of the particles include at least one binding moiety specific to a target, into a sample to form at least one target/particle complex and applying a magnetic field to isolate the magnetic particle/target complexes from the sample. The process starts at inputting a sample into the system and ends at delivering a capture target or nucleic acids of the target into a container for further analysis. | ||||||
| 98 | Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes | US15083584 | 2016-03-29 | US09598482B2 | 2017-03-21 | Roberto Burioni; Massimo Clementi |
| Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines. | ||||||
| 99 | AVIAN REOVIRUS VACCINES | US15223623 | 2016-07-29 | US20170028055A1 | 2017-02-02 | Holly S. Sellers |
| The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses. | ||||||
| 100 | METHOD FOR DETECTING COLIFORM BACTERIA CONTAINED IN MILK | US15105420 | 2014-12-17 | US20160320387A1 | 2016-11-03 | Koji MAEHANA; Kenji MATSUYAMA |
| The object is to provide a lysis method, lysis treatment solution, detection method using an immunochromatographic device, and detection kit comprising an immunochromatographic device for detecting whether causative bacteria of mastitis are coliform bacteria or not by using milk of a livestock animal. There is provided a method for lysing coliform bacteria, which comprises the step of mixing a lysis agent containing a lytic enzyme, and at least one kind of anionic surfactant, and preferably further containing at least one kind of nonionic surfactant, with milk obtained form a livestock animal to lyse coliform bacteria existing in the milk. The lytic enzyme is preferably lysozyme. | ||||||
QQ群二维码
意见反馈
意见反馈